Research Index
Rapamycin/mTOR Peptide Inhibitors Research Index
PSI surfaces 50 peer-reviewed studies on Rapamycin/mTOR Peptide Inhibitors, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
Chow KBS
Indian J Pharmacol·2026·Animal·Neuroprotection·PubMed →
Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.
Pobee E, Daziani G, Gameli PS et al.
J Anal Toxicol·2025·Animal·PubMed →
Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator.
Gauvin J, Huynh DN, Dubuc I et al.
Front Pharmacol·2024·Animal·PubMed →
Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.
Hossain S, Kneiszl R, Larsson P
Nanoscale·2023·Animal·PubMed →
Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.
Guan C, Li C, Shen X et al.
Eur J Med Res·2023·Animal·PubMed →
Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein.
Meanti R, Licata M, Rizzi L et al.
Int J Mol Sci·2023·Animal·PubMed →
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
Jiang B, Wang M, Li X et al.
Microvasc Res·2022·Animal·Anti-Inflammatory·PubMed →
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models.
Waddingham MT, Tsuchimochi H, Sonobe T et al.
Front Physiol·2021·Animal·PubMed →
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.
Zambelli V, Rizzi L, Delvecchio P et al.
Drug Target Insights·2021·Animal·PubMed →
Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats.
Dahlgren D, Olander T, Sjöblom M et al.
Acta Pharm Sin B·2021·Animal·PubMed →
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.
Meanti R, Rizzi L, Bresciani E et al.
Pharmaceuticals (Basel)·2021·Animal·PubMed →
Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice.
Huang Z, Lu X, Huang L et al.
FASEB J·2021·Animal·GH Activity, Liver Protection, Weight Loss·PubMed →
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.
Baser T, Ozdemir E, Filiz AK et al.
Can J Physiol Pharmacol·2021·Animal·PubMed →
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.
McDonald H, Peart J, Kurniawan ND et al.
Biomed Pharmacother·2020·Animal·Anti-Inflammatory·PubMed →
The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin.
Dahlgren D, Sjöblom M, Hedeland M et al.
Pharmaceutics·2020·Animal·PubMed →
Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.
Agbo E, Li MX, Wang YQ et al.
Pharmazie·2019·Animal·PubMed →
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice.
Cheng XL, Ding F, Wang DP et al.
Peptides·2019·Animal·Cardiovascular Risk·PubMed →
Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.
Agbo E, Liu D, Li M et al.
Turk J Med Sci·2019·Animal·PubMed →
Characterization of a third ghrelin receptor, GHS-R3a, in channel catfish reveals novel expression patterns and a high affinity for homologous ligand.
Small BC, Quiniou SMA, Kaiya H et al.
Comp Biochem Physiol A Mol Integr Physiol·2019·Animal·PubMed →
Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: Progress, outlook, and challenges.
Sardela VF, Anselmo CS, Nunes IKDC et al.
Drug Test Anal·2018·Animal·PubMed →
Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans.
Prodam F, Benso A, Gramaglia E et al.
Neuropeptides·2008·Human·GH Activity·PubMed →
d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans.
Benso A, Prodam F, Lucatello B et al.
Neuropeptides·2007·Human·GH Activity·PubMed →
There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients.
Janssen JA, Poldermans D, Hofland LJ et al.
J Endocrinol Invest·2004·Human·GH Activity·PubMed →
Age-related differences in growth hormone (GH) regulation during strenuous exercise.
de Vries WR, Lambers M, van Zanten DP et al.
Horm Metab Res·2004·Human·GH Activity·PubMed →
Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.
Frieboes RM, Antonijevic IA, Held K et al.
Psychoneuroendocrinology·2004·Human·GH Activity, Sleep·PubMed →
Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors.
Arnaldi G, Mancini T, Kola B et al.
J Clin Endocrinol Metab·2003·Human·PubMed →
Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans.
Benso A, Gottero C, Prodam F et al.
J Endocrinol Invest·2003·Human·Glycemic Control·PubMed →
GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.
Oliveira JH, Vieira JG, Abucham J et al.
J Endocrinol Invest·2003·Human·PubMed →
A practical approach to the diagnosis of growth hormone (GH) deficiency in patients transitioning to adulthood using GH stimulation testing.
Styne DM
J Pediatr Endocrinol Metab·2003·Human·GH Activity·PubMed →
Age-related variations of the GH response to GH secretagogues in humans.
Gottero C, Benso A, Prodam F et al.
J Endocrinol Invest·2002·Human·Longevity, GH Activity·PubMed →
Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans.
Broglio F, Benso A, Gottero C et al.
Clin Endocrinol (Oxf)·2002·Human·GH Activity·PubMed →
Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
Broglio F, Guarracino F, Benso A et al.
Eur J Pharmacol·2002·Human·GH Activity·PubMed →
GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.
Imazio M, Bobbio M, Broglio F et al.
Eur J Heart Fail·2002·Human·GH Activity·PubMed →
Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
Maccario M, Veldhuis JD, Broglio F et al.
Eur J Endocrinol·2002·Human·GH Activity·PubMed →
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.
Broglio F, Arvat E, Benso A et al.
J Clin Endocrinol Metab·2001·Human·Glycemic Control, GH Activity·PubMed →
Biologic activities of growth hormone secretagogues in humans.
Ghigo E, Arvat E, Giordano R et al.
Endocrine·2001·Human·GH Activity·PubMed →
Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.
Broglio F, Benso A, Valetto MR et al.
Endocrine·2001·Human·GH Activity·PubMed →
Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
Gianotti L, Ramunni J, Lanfranco F et al.
J Endocrinol Invest·2001·Human·GH Activity·PubMed →
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Arvat E, Maccario M, Di Vito L et al.
J Clin Endocrinol Metab·2001·Human·GH Activity·PubMed →
The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients.
Murray RD, Peacey SR, Rahim A et al.
Clin Endocrinol (Oxf)·2001·Human·GH Activity·PubMed →
Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
Arvat E, Maccagno B, Ramunni J et al.
Eur J Endocrinol·2000·Human·GH Activity·PubMed →
Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.
Broglio F, Benso A, Gottero C et al.
Eur J Endocrinol·2000·Human·GH Activity·PubMed →
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients.
Grottoli S, Arvat E, Gauna C et al.
Int J Obes Relat Metab Disord·2000·Human·Weight Loss·PubMed →
Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.
Coiro V, Volpi R, Capretti L et al.
J Intern Med·2000·Human·PubMed →
Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.
De Marinis L, Mancini A, Valle D et al.
Horm Metab Res·2000·Human·GH Activity·PubMed →
The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.
Bellone J, Bellone S, Aimaretti G et al.
J Endocrinol Invest·2000·Human·GH Activity·PubMed →
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Grottoli S, Arvat E, Gauna C et al.
Pituitary·1999·Human·GH Activity, Weight Loss·PubMed →
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
Benso A, Broglio F, Gottero C et al.
J Endocrinol Invest·1999·Human·GH Activity·PubMed →
Growth hormone secretagogues: mechanism of action and use in aging.
Fuh VL, Bach MA
Growth Horm IGF Res·1998·Human·Longevity, GH Activity·PubMed →
Does desensitization to hexarelin occur?
Rahim A, Shalet SM
Growth Horm IGF Res·1998·Human·GH Activity·PubMed →